BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Expands Medical Board with Appointment of Triple-Certified Cardiologist

April 20, 2021 13:44:36

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based and proprietary products for heart and brain health through its subsidiaries, BergametNA(TM) and Ultimate Brain Nutrients(TM), today announced that Dr. Joel Kahn, M.D., a world-renowned, triple board-certified cardiology specialist, has joined Healthy Extracts. According to the update, Dr. Kahn has utilized BergametNA Citrus Bergamot SuperFruit(TM) with thousands of patients and has seen positive cardiovascular benefits and arterial age reversal and flexibility. “We are so excited to welcome Dr. Joel Kahn, one of the few triple-certified cardiologists in the entire U.S., to our Medical Board,” said Duke Pitts, director, president and CEO of Healthy Extracts. “Dr. Kahn’s agreement to join our Medical Board, based on CIMT results of our heart health products, is truly an exciting development. His addition rounds out our incredibly talented and specialized group of doctors and athletes who are committed to the company’s ‘Live Life Young Again’ philosophy. Dr. Kahn will be instrumental in expanding our doctor-to-doctor and consumer sales.”

To view the full press release, visit

About Healthy Extracts Inc.

Healthy Extracts serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched. Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents – two issued and four pending. For more information visit:, or

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork